PhotoPharmics (American Fork, UT) completes enrollment in its 350-participant, fully remote Phase 3 trial testing the Celeste® light-therapy device for Parkinson’s, a non-drug, home-based treatment targeting non-motor symptoms through photo-neuromodulation.
American Fork, Utah — November 6, 2025
Utah medtech startup completes enrollment of 350 participants in its pivotal Phase 3 trial of Celeste®, a home-use device designed to ease Parkinson’s symptoms through light stimulation.
Lindon-based PhotoPharmics has surpassed its enrollment goal for a first-of-its-kind, fully remote Phase 3 clinical trial testing its Celeste® light-therapy device for Parkinson’s disease. The pivotal “Light for PD” study closed enrollment at 350 participants nationwide, making it one of the largest decentralized medical-device trials conducted to date.
Celeste is a non-drug, at-home therapy that delivers precisely calibrated light through the eyes to activate retinal cells connected to brain regions controlling sleep, alertness, and mood. The goal: restore natural signaling that weakens in Parkinson’s and contributes to non-motor symptoms such as fatigue, anxiety, sleep disruption, and cognitive decline. Improving those areas can, in turn, enhance motor performance and overall quality of life.
Unlike traditional site-based studies, PhotoPharmics’ trial is conducted entirely through telemedicine. Participants use the device at home and connect with study teams via secure video visits. “This design shows that rigorous, large-scale research can meet patients where they live,” said CEO Kent Savage.
“We’re proving that rigorous science can be both patient-centered and home-based. Every participant who volunteered for this study helped bring new hope to millions living with Parkinson’s," he added.
Founded by light-therapy veterans who previously developed technology later acquired by Philips-Respironics, PhotoPharmics has spent more than a decade refining photo-neuromodulation — the use of targeted light to influence neural systems. The company’s work builds on that foundation to create accessible, home-based therapies for neurodegenerative disease.
“Our mission is to make treatments that fit into life, not the other way around,” Savage said.
PhotoPharmics is part of Utah’s growing medtech ecosystem, which has seen rising investment in digital and home-based healthcare solutions. In April 2025 the American Fork-based medtech c0mpany with an office also in Lehi raised a $6 million Series B extension, led by Kickstart Fund. It followed a $16 million investment round in November 2023, also led by Kickstart, bringing recent funding to over $22 million.
The FDA has granted Celeste Breakthrough Device designation, recognizing its potential to address significant unmet needs in Parkinson’s care.
Top-line results from the Phase 3 trial are expected in mid-2026.
Learn more at www.photopharmics.com
